PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1731152
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1731152
The global neurostimulation devices market was valued at USD 7.2 billion in 2024 and is projected to grow robustly to USD 15.1 billion by 2032. This impressive growth, at a CAGR of 9.8% during the forecast period from 2025 to 2032, is fueled by rising prevalence of neurological disorders such as Parkinson's disease, epilepsy, and chronic pain conditions. Increasing adoption of advanced neurostimulation therapies, along with technological innovations in device design and functionality, is significantly driving market expansion.
Growing awareness among healthcare providers and patients about the benefits of neurostimulation in improving quality of life, combined with favorable reimbursement policies in developed regions, is accelerating product adoption. Moreover, investments in R&D and strategic collaborations by key market players are contributing to the rapid advancement and diversification of neurostimulation devices.
Key Insights
The neurostimulation devices market size was USD 7.2 billion in 2024 and is expected to reach USD 15.1 billion by 2032, growing at a CAGR of 9.8%.
Implantable/internal devices dominate the market, widely used for managing chronic pain.
Deep brain stimulation devices are gaining traction, especially for neurological conditions like Parkinson's disease and epilepsy.
North America holds the largest market share, supported by advanced healthcare infrastructure and strong reimbursement frameworks.
The Asia-Pacific region is forecast to grow at the highest CAGR, driven by increasing awareness, rising incidence of neurological disorders, and improving healthcare access.
Technological advancements such as minimally invasive devices and wireless neurostimulation systems are enhancing patient comfort and treatment outcomes.
Major companies including Medtronic, Boston Scientific, and Abbott Laboratories are investing in product innovation and expanding their global footprint.
Increasing prevalence of chronic pain and neurological disorders worldwide is driving consistent demand for neurostimulation therapies.
Emerging applications in areas such as migraine management and depression are opening new market opportunities.
Regulatory support for innovation and safety standards is fostering greater adoption of neurostimulation devices across various geographies.